EQUITY RESEARCH – RESULTS FLASH

MEGA LIFESCIENCES

MEGA TB

1Q24 results at first glance

Core profit miss on lower sales

Highlights

- MEGA posted a net profit of THB478m in 1Q24 (+1.0% q-q, +5.4% y-y-y). Excluding an FX loss of THB151m from the depreciation of the Nigerian Naira, and the loss from new businesses, MEGA's core profit was THB494m (-20.5% q-q, -9.5% y-y).
- The core profit was 12% lower than our estimate mainly due to lowerthan-expected revenue from the branded business, Mega We Care, and higher-than-expected SG&A expenses.
- Total revenue came in at THB3.7b, a decrease of 10.2% q-q due to seasonality, but was flat y-y. Mega We Care revenue was at THB1.9b (52% of total revenue), a decline of 9.2% q-q and 1.1% y-y. This was partly from the 32% y-y drop in revenue from Nigeria as the Naira's depreciation deteriorated consumers' purchasing power.
- Its Maxxcare distribution business (47% of total revenue) fell 12.2% q-q but rose 1.2% y-y to THB1.7b. The gross margin for Maxxcare improved to 27.9% from 26.6% in 4Q23 and 20.4% y-y, mainly due to the dual currency rate effect in Myanmar. Normalizing the dual Kyat currency, this unit's gross margin was stable q-q at 25.0%, but improved from 19.8% in 1Q23 due to the loss of low-margin customers in Myanmar since 1Q23.
- The SG&A expense to revenue ratio increased to 28.6% in 1Q24. We believe the company used promotional and marketing campaigns to revive sales.

Outlook

- The core profit in 1Q24 accounts for 20% of our full-year projection. We maintain our forecast and DCF-based TP of THB56 (8.2% WACC, 3.5% LTG), implying 20x 2024E P/E, close to its five-year average.
- Despite experiencing low growth and a lackluster story in 2024, MEGA is a leading brand in the health and wellness industry, especially in underpenetrated markets. We retain our BUY call on the cheap valuations.



KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	15,681	16,139	16,927	17,736
Net profit	1,993	2,444	2,598	2,715
EPS (THB)	2.29	2.80	2.98	3.11
vs Consensus (%)	-	(2.5)	(2.9)	(5.8)
EBITDA	3,285	3,201	3,389	3,535
Recurring net profit	2,699	2,444	2,598	2,715
Core EPS (THB)	3.10	2.80	2.98	3.11
EPS growth (%)	13.4	(9.4)	6.3	4.5
Core P/E (x)	13.1	14.4	13.6	13.0
Dividend yield (%)	4.0	3.8	4.0	4.2
EV/EBITDA (x)	10.0	10.2	9.6	9.1
Price/book (x)	3.8	3.6	3.4	3.3
Net debt/Equity (%)	(26.4)	(26.3)	(27.5)	(27.7)
ROE (%)	29.9	25.5	25.7	25.8



Share price performance	1 Mo	nth	3 Month	12 Month
Absolute (%)	(1	1.2)	(2.4)	(2.4)
Relative to country (%)		0.5	(1.0)	11.0
Mkt cap (USD m)				959
3m avg. daily turnover (USD m)				1.2
Free float (%)				40
Major shareholder		Un	istretch Co	Ltd (50%)
12m high/low (THB)			4	6.75/34.75
Issued shares (m)				871.87

Sources: Bloomberg consensus; FSSIA estimates



Jitra Amornthum Fundamental Investment Analyst on Securities; License no. 014530 jitra.a@fssia.com, +66 2646 9966


PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Exhibit 1: MEGA - 1Q24 results summary

Year to Dec 31	1Q23	2Q23	3Q23	4Q23	1Q24	Cha	nge	2024E	Change	% of
	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)	2024E				
Sales	3,728	3,992	3,803	4,158	3,733	(10.2)	0.1	16,139	2.9	23.1
Cost of sales	(2,102)	(2,167)	(2,064)	(2,252)	(1,984)	(11.9)	(5.6)	(8,816)	2.7	22.5
Gross profit	1,626	1,825	1,739	1,905	1,749	(8.2)	7.5	7,323	3.2	23.9
Operating costs	(1,028)	(1,038)	(1,021)	(1,104)	(1,066)	(3.4)	3.8	(4,483)	7.0	23.8
Operating profit	599	787	718	801	682	(14.8)	14.0	11,807	4.6	5.8
Operating EBITDA	685	877	815	908	775	(14.6)	13.1	3,201	(2.6)	24.2
Other income	18	19	27	31	22	(30.2)	24.7	65	(32.1)	33.9
Interest expense	(9)	(9)	(8)	(5)	(5)	11.0	(44.6)	(27)	(12.9)	18.8
Profit before tax	607	797	737	828	699	(15.6)	15.2	2,877	(3.1)	24.3
Тах	(73)	(40)	(98)	(58)	(71)	21.3	(2.9)	(432)	60.4	16.4
Reported net profit	453	531	536	473	478	1.0	5.4	2,444	22.7	19.5
Extraordinaries										
- Net loss from new businesses	12	7	11	10	9					
- FX los/(gain)	81	151	(38)	138	7					
- Normalising tax expense	0	(48)	17	0	0					
Core profit	546	641	526	621	494	(20.5)	(9.5)	2,444	5.0	20.2
Reported EPS (THB)	0.52	0.61	0.61	0.54	0.55	1.0	5.4	2.80	22.7	19.5
Core EPS (THB)	0.63	0.74	0.60	0.71	0.57	(20.5)	(9.5)	2.80	5.0	20.2
Key ratios (%)	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)	
Gross margin	43.6	45.7	45.7	45.8	46.8	1.0	3.2	45.4	0.1	
Operating margin	16.5	20.2	19.6	20.0	18.9	(1.2)	2.3	18.0	(1.1)	
EBITDA margin	18.4	22.0	21.4	21.8	20.8	(1.1)	2.4	19.8	(1.1)	
Recurring net margin	14.6	16.1	13.8	14.9	13.2	(1.7)	(1.4)	15.1	0.3	
SG&A / Sales	27.6	26.0	26.8	26.6	28.6	2.0	1.0	27.8	1.1	
Revenue breakdown	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)					
Branded business	1,953	2,019	1,907	2,126	1,930	(9.2)	(1.1)	8,502	6.2	
Distribution business	1,717	1,876	1,825	1,980	1,737	(12.2)	1.2	7,319	(1.0)	
OEM business	59	97	71	53	65	23.4	9.8	317	13.6	
Gross margin by BU (%)	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)	
Branded business	64.6	65.8	65.3	64.3	64.3	0.0	(0.3)	64.6	(0.4)	
Distribution business	20.4	24.5	25.9	26.6	27.9	1.3	7.5	23.8	(0.7)	
OEM business	24.6	37.6	27.9	25.6	34.9	9.3	10.2	28.0	(2.2)	


Sources: MEGA, FSSIA estimates

Exhibit 2: Revenue structure



Sources: MEGA, FSSIA's compilation

Exhibit 3: Margins and core profit



Sources: MEGA, FSSIA's compilation

Financial Statements

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	15,686	15,681	16,139	16,927	17,736
Cost of goods sold	(8,647)	(8,586)	(8,816)	(9,206)	(9,640)
Gross profit	7,040	7,095	7,323	7,720	8,097
Other operating income	80	95	65	68	71
Operating costs	(4,359)	(4,191)	(4,483)	(4,706)	(4,948)
Operating EBITDA	3,033	3,285	3,201	3,389	3,535
Depreciation	(272)	(286)	(297)	(307)	(316)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	2,761	2,999	2,904	3,082	3,219
Net financing costs	(29)	(31)	(27)	(25)	(25)
Associates	0	0	0	0	0
Recurring non-operating income	2	0	(1)	(1)	0
Non-recurring items	(138)	(707)	0	0	0
Profit before tax	2,596	2,262	2,876	3,056	3,194
Tax	(355)	(269)	(432)	(459)	(479)
Profit after tax	2,242	1,993	2,444	2,598	2,715
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	2,242	1,993	2,444	2,598	2,715
Non-recurring items & goodwill (net)	138	707	0	0	0
Recurring net profit	2,380	2,699	2,444	2,598	2,715
Per share (THB)					
Recurring EPS *	2.73	3.10	2.80	2.98	3.11
Reported EPS	2.57	2.29	2.80	2.98	3.11
DPS	1.60	1.60	1.54	1.64	1.71
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth					
Revenue (%)	11.0	0.0	2.9	4.9	4.8
Operating EBITDA (%)	23.2	8.3	(2.6)	5.9	4.3
Operating EBIT (%)	26.2	8.6	(3.2)	6.1	4.4
Recurring EPS (%)	30.2	13.4	(9.4)	6.3	4.5
Reported EPS (%)	15.1	(11.1)	22.7	6.3	4.5
Operating performance					
Gross margin inc. depreciation (%)	44.9	45.2	45.4	45.6	45.6
Gross margin exc. depreciation (%)	46.6	47.1	47.2	47.4	47.4
Operating EBITDA margin (%)	19.3	21.0	19.8	20.0	19.9
Operating EBIT margin (%)	17.6	19.1	18.0	18.2	18.1
Net margin (%)	15.2	17.2	15.1	15.3	15.3
Effective tax rate (%)	13.7	11.9	15.0	15.0	15.0
Dividend payout on recurring profit (%)	58.6	51.7	55.0	55.0	55.0
Interest cover (X)	96.2	96.0	106.7	121.0	131.2
Inventory days	172.8	164.6	150.0	150.8	150.6
Debtor days	72.0	80.9	82.9	83.0	82.1
Creditor days	163.5	157.6	138.4	135.7	132.9
Operating ROIC (%)	56.8	58.0	47.6	47.3	47.3
ROIC (%)	37.7	39.8	33.6	34.0	34.4
ROE (%)	28.4	29.9	25.5	25.7	25.8
ROA (%)	17.2	19.0	17.1	17.4	17.6
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Mega We Care	8,053	8,005	8,502	9,097	9,552
Maxxcare	7,320	7,397	7,319	7,502	5,552 7,847
	1,020	.,001	.,010	.,	1,011

Sources: Mega Lifesciences; FSSIA estimates

Financial Statements Mega Lifesciences

ash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
ecurring net profit	2,380	2,699	2,444	2,598	2,715
epreciation	272	286	297	307	316
sociates & minorities	0	0	0	0	(
her non-cash items	474	671	(47)	(244)	(335
ange in working capital	(989)	(1,023)	(845)	(663)	(723
sh flow from operations	2,136	2,633	1,850	1,998	1,973
apex - maintenance	-	-	-	-	
apex - new investment	(305)	(294)	(330)	(300)	(340
et acquisitions & disposals	-	-	-	-	
ther investments (net)	24	44	0	0	(
ash flow from investing	(281)	(250)	(330)	(300)	(340
ividends paid	(1,406)	(1,439)	(1,344)	(1,429)	(1,493
quity finance	0	0	0	0	(
ebt finance	2	(237)	(9)	23	(5
ther financing cash flows	(30)	(32)	(27)	(25)	(25
ash flow from financing	(1,433)	(1,708)	(1,380)	(1,431)	(1,523
on-recurring cash flows	-	-	-	-	
ther adjustments	0	0	0	0	(
et other adjustments	(165)	(751)	0	0	(
ovement in cash	257	(76)	139	267	110
ee cash flow to firm (FCFF)	1,884.18	2,414.24	1,546.77	1,723.07	1,657.357
ee cash flow to equity (FCFE)	1,662.783	1,362.983	1,483.564	1,695.36	1,603.49
r share (THB)					
FF per share	2.16	2.77	1.77	1.98	1.90
CFE per share	1.91	1.56	1.70	1.94	1.84
ecurring cash flow per share	3.58	4.19	3.09	3.05	3.09
alance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	4,062	4,309	4,639	4,939	5,279
ess: Accumulated depreciation	(2,161)	(2,334)	(2,631)	(2,938)	(3,254
angible fixed assets (net)	1,901	(2,354) 1,974	2,008	2,001	2,025
tangible fixed assets (net)	1,329	1,318	1,344	1,353	1,343
ong-term financial assets	0	0	0	0	1,040
vest. in associates & subsidiaries	223	221	221	221	22
ash & equivalents	2,789	2,712	2,851	3,118	3,228
/C receivable	3,382	3,570	3,758	3,942	4,033
ventories	4,109	3,377	3,623	3,733	3,962
ther current assets	310	330	345	333	344
urrent assets	10,590	9,990	10,578	11,126	11,567
ther assets	603	611	592	593	594
otal assets	14,646	14,115	14,743	15,294	15,750
ommon equity	8,777	9,302	9,902	10,351	10,723
inorities etc.	0	0	0	0	(
otal shareholders' equity	8,777	9,302	9,902	10,351	10,723
ong term debt	109	132	125	151	148
ther long-term liabilities	223	244	299	313	328
ong-term liabilities	332	376	424	464	476
/C payable	3,972	3,197	3,261	3,355	3,433
hort term debt	312	120	118	116	114
ther current liabilities	1,254	1,119	1,039	1,009	1,004
urrent liabilities	5,538	4,437	4,417	4,479	4,55
otal liabilities and shareholders' equity	14,646	14,115	14,743	15,294	15,750
et working capital	2,575	2,961	3,428	3,645	3,902
vested capital	6,632	7,086	7,592	7,813	8,085
ncludes convertibles and preferred stock which is beir	ng treated as debt				
er share (THB)					
ook value per share	10.07	10.67	11.36	11.87	12.30
angible book value per share	8.54	9.16	9.82	10.32	10.76
nancial strength					
et debt/equity (%)	(27.0)	(26.4)	(26.3)	(27.5)	(27.7
et debt/total assets (%)	(16.2)	(17.4)	(17.7)	(18.6)	(18.8
urrent ratio (x)	1.9	2.3	2.4	2.5	2.5
interest cover (x)	69.5	54.0	67.6	79.4	80.2
luation	2022	2023	2024E	2025E	20265
ecurring P/E (x) *	14.8	13.1	14.4	13.6	13.
ecurring P/E @ target price (x) *	20.5	18.1	20.0	18.8	18.0
eported P/E (x)	15.8	17.7	14.4	13.6	13.0
vidend yield (%)	4.0	4.0	3.8	4.0	4.2
ice/book (x)	4.0	3.8	3.6	3.4	3.3
ice/tangible book (x)	4.0	4.4	4.1	3.9	3.8
//EBITDA (x) **	10.9	10.0	10.2	9.6	9.1
V/EBITDA @ target price (x) **	15.3	14.1	14.4	13.6	13.0
	10.3				

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Mega Lifesciences; FSSIA estimates



MEGA LIFESCIENCES PCL (MEGA TB)

FSSIA ESG rating

 $\star \star \star$

54.48 /100

Exhibit 4: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA		Domestic ratings					Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
COM7	61.78		Y	Y	5.00	5.00	Certified	Low	47.75			52.68	21.00	4.40	43.59
MEGA	54.48		Y	Y	4.00	4.00	Declared	Medium	66.56			58.59	24.00	2.39	
BJC	71.33	Y	Y	Y	4.00	4.00		Medium	55.09	A		65.19	89.00	2.16	
CRC	64.49		Y	Y	5.00	5.00	Certified	Medium		BBB		60.98	73.00	2.90	47.27

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.29	_
BESG environmental pillar score	_	1.86	—
BESG social pillar score	_	1.06	_
BESG governance pillar score	_	4.54	_
ESG disclosure score	44.34	53.36	—
Environmental disclosure score	29.84	44.22	—
Social disclosure score	19.44	32.16	_
Governance disclosure score	83.59	83.59	_
Environmental			
Emissions reduction initiatives	Yes	Yes	Yes
Climate change policy	Yes	Yes	No
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	_	633
GHG scope 2 location-based	_	_	6
GHG Scope 3	_	_	0
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	Yes	Yes	Yes
Total energy consumption	24	24	23
Renewable energy use	1	1	1
Electricity used	12	13	12
Fuel used - natural gas	_	_	914

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	Yes	Yes	Yes
Hazardous waste	_	—	0
Total waste	1	1	1
Waste recycled	0	0	—
Waste sent to landfills	_	_	_
Environmental supply chain management	Yes	Yes	No
Water policy	No	Yes	Yes
Water consumption	_	_	0
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	Yes	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	56	56	56
Pct disabled in workforce	_	_	_
Business ethics policy	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	Yes	Yes	No
Lost time incident rate - employees	0	0	_
Total recordable incident rate - employees	_	_	_
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	5,714	6,021	5,767
Employee turnover pct		19	
Total hours spent by firm - employee training	70,551	79,892	70,826
Social supply chain management	Yes	Yes	Yes
Governance			
Board size	10	10	10
No. of independent directors (ID)	4	4	4
No. of women on board	1	1	1
No. of non-executive directors on board	8	8	8
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	6	5	7
Board meeting attendance pct	100	96	94
Board duration (years)	3	30	34
Director share ownership guidelines	No	No	No
Age of the youngest director	32	33	34
Age of the oldest director	80	81	82
No. of executives / company managers	6	6	6
No. of female executives	1	1	1
Executive share ownership guidelines	No	No	No
Size of audit committee	3	3	3
No. of ID on audit committee	3	3	3
Audit committee meetings	4	4	4
Audit meeting attendance %	100	100	100
Size of compensation committee	3	3	3
No. of ID on compensation committee	1	1	1
No. of compensation committee meetings	2	2	2
Compensation meeting attendance %	100	100	100
Size of nomination committee	3	3	3
No. of nomination committee meetings	2	2	3
Nomination meeting attendance %	100	100	100
Sustainability governance			
Verification type	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	IY .			Rating						
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com ual S&P Glob -ranked comp	transparent, rules-based npanies' Total Sustainabi pal Corporate Sustainabil panies within each industr	ility Scores resulting ity Assessment (CSA). ry are selected for	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Globa ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.						
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing r	usiness with tr must pass the ar trading of th shareholders ome key disq pendent direc related to CG	ility in Environmental and ransparency in Governan a preemptive criteria, with he board members and e s, and combined holding i ualifying criteria include: ctors and free float violati a social & environmental earnings in red for > 3 year	ace, updated annually. a two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	nature of the relevant industry and materiality.						
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	the Thai IOD,	th in sustainable develop with support from the St Its are from the perspecti Is.	ock Exchange of	Good (80-89), and not rated for equitable treatr	3 for Good (70 or scores belo nent of shareh 25%); 4) disclo	ories: 5 for Excel -79), 2 for Fair (6 w 50. Weightings olders (weight 2: sure & transpare	0-69), 1 for P include: 1) th 5% combined	ass (60-69), le rights; 2) and); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of s exercised. The and verifiability	e incorporated and sufficientl e CG compor r AGM proced and after the i ufficient informa e second assess r; and 3) openne	which shareholders' right d into business operation y disclosed. All form impu- nents to be evaluated anr dures before the meeting meeting (10%). (The first a stion for voting; and 2) facilita ses 1) the ease of attending n ess for Q&A. The third involve ues, resolutions and voting re	is and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be meetings; 2) transparency es the meeting minutes that			four categories: (80-89), and not				
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contr certification eciding to becom Intent to kick off acluding risk ass employees, est	Checklist include corrupti rols, and the monitoring a is good for three years. me a CAC certified member s f an 18-month deadline to sul sessment, in place of policy a tablishment of whistleblowing all stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for ind control, training of	passed Checkl	ist will move fo se members a	ed by a committe or granting certific re twelve highly r chievements.	ation by the 0	CAC Council		
<u>Morningstar</u> <u>Sustainalytics</u>	based on an risk is unmar regulatory filing	assessment naged. Source gs, news and ot	ytics' ESG risk rating provides an overall company score issessment of how much of a company's exposure to ESG aged. Sources to be reviewed include corporate publications and is, news and other media, NGO reports/websites, multi-sector papy feedback, ESG controversies, issuer feedback on draft ESG						ed risk. The Severe		
		uality & peer rev			0-10	10-20	20-30	30-40	40+		
<u>ESG Book</u>	positioned to the principle helps explair over-weightir	o outperform o of financial m n future risk-a	sustainable companies th over the long term. The m nateriality including inform djusted performance. Ma ith higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s dicating better p	core is scaled			
<u>MSCI</u>			measure a company's m nd laggards according to						nethodology to		
	AAA AA	8.571-10.00 7.143-8.570	Leader:	leading its industry in m	nanaging the most s	gnificant ESG ri	sks and opportunitie	s			
	A	5.714-7.142									
	BBB	4.286-5.713	3 Average:	a mixed or unexception industry peers	al track record of ma	anaging the mos	t significant ESG ris	ks and opportu	nities relative to		
	BB	2.857-4.28	5	maddiy poolo							
	В	1.429-2.856	Laggard:	lagging its industry bas	ed on its high expos	ure and failure to	o manage significan	t ESG risks			
Moody's ESG	CCC Moody's ass	0.000-1.428	⁸ gree to which companies	take into account ESC o	hiectives in the d	efinition and in	nnlementation of	their strategy	nolicies It		
solutions	believes that	t a company ii	ntegrating ESG factors in or shareholders over the	nto its business model an							
<u>Refinitiv ESG</u> rating	based on pu	blicly available	and objectively measure and auditable data. The ata publicly. <i>(Score ratings a</i>	e score ranges from 0 to	100 on relative E	SG performar	ce and insufficie	nt degree of t			
S&P Global			ore is a relative score mean nin the same industry clas				of ESG risks, op	oortunities, ar	d impacts		
	ESG Score		-	ating the company's agg	regated Environn	nental, Social					
Bloomberg				mberg's view of ESG fina the weights are determine							

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 40.50	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 13-May-2024 unless otherwise stated.



RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.